Symtuza and Weight decreased - a phase IV clinical study of FDA data

Summary:

Weight decreased is reported as a side effect among people who take Symtuza (darunavir;cobicistat;emtricitabine;tenofovir alafenamide), especially for people who are male, 50-59 old, also take Truvada, and have Acquired immunodeficiency syndrome.

The phase IV clinical study analyzes which people have Weight decreased when taking Symtuza. It is created by eHealthMe based on reports of 3,138 people who have side effects when taking Symtuza from the FDA, and is updated regularly.

What is Symtuza?

Symtuza has active ingredients of darunavir;cobicistat;emtricitabine;tenofovir alafenamide. It is often used in hiv infection. eHealthMe is studying from 3,149 Symtuza users. Check the latest studies of Symtuza.

What is Weight decreased?

Weight decreased is found to be associated with 3,393 drugs and 4,744 conditions by eHealthMe. Check the latest studies of Weight decreased.

On Jul, 15, 2026

3,138 people reported to have side effects when taking Symtuza.
Among them, 36 people (1.15%) have Weight decreased.

Among these 36 people:

What is the gender of people who have Weight decreased when taking Symtuza? *

female: 18.52 %
male: 81.48 %

What is the age of people who have Weight decreased when taking Symtuza? *

What are other drugs people take besides Symtuza? *

What are other side effects people have besides Weight decreased? *

Chronic Kidney Disease: 11 people, 30.56%
Bone Density Decreased: 11 people, 30.56%
Rickets (softening of bones): 10 people, 27.78%
Eating Disorder: 9 people, 25.00%
Tooth Loss: 9 people, 25.00%
Joint Pain: 6 people, 16.67%
Abdominal Distension: 4 people, 11.11%
Headache (pain in head): 4 people, 11.11%
Bone Pain: 4 people, 11.11%
Diarrhea: 3 people, 8.33%

What are the existing conditions these people have? *

Ill-Defined Disorder: 3 people, 8.33%
Depression: 3 people, 8.33%
Acquired Immunodeficiency Syndrome (disease of the human immune system caused by the human immunodeficiency virus (hiv)): 3 people, 8.33%
Stress And Anxiety: 1 person, 2.78%
Neuropathy Peripheral (surface nerve damage): 1 person, 2.78%
High Blood Cholesterol: 1 person, 2.78%
Hepatitis B: 1 person, 2.78%
Hepatitis (inflammation of the liver): 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Symtuza and have Weight decreased?

- Check whether Weight decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Symtuza:

Symtuza (3,149 reports)

Weight decreased treatments and more:

Weight decreased (364,522 reports)

How severe was Weight decreased and when was it recovered:

Weight decreased in Symtuza

Expand to all the drugs that have ingredients of darunavir;cobicistat;emtricitabine;tenofovir alafenamide:

Weight decreased and drugs with ingredients of darunavir;cobicistat;emtricitabine;tenofovir alafenamide

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Symtuza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight decreased:

Weight decreased (3,393 drugs)

Browse all the conditions that are associated with Weight decreased:

Weight decreased (4,744 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on darunavir;cobicistat;emtricitabine;tenofovir alafenamide (the active ingredients of Symtuza) and Symtuza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.